Back to search

Finland· FI-REL-REL62120

Bortezomib Glenmark

A bortezomib product containing bortezomib, registered in Finland by Glenmark Arzneimittel GmbH. The same ATC class is registered in 15 of our 19 countries.

ATC L01XG01

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedBortezomib GlenmarkATCL01XG01REGISTER NO.FI-REL-REL62120PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Bortezomib is registered in 15 of 19 countries.

Countries holding a registration under ATC L01XG01 (bortezomib), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 8 of them publish a price we can compare per daily dose

Bortezomib · ATC L01XG01

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of bortezomib costs, country by country.

Normalised to the WHO defined daily dose (0.45 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Bortezomib · price per daily dose (0.45 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$66.46
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Fimea (Finland)
Active substance
Bortezomib
Manufacturer
Glenmark Arzneimittel GmbH
Country
Finland (FI)
ATC code
L01XG01
ATC class
Bortezomib
Defined daily dose
0.45 mg, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

587 interactions on record for bortezomib.

Graded by severity as the source publishes them — 45 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Bortezomib · interactions on record

587 records

  • 45 severe
  • 250 moderate
  • 66 minor
  • 226 info

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • RifampicinJ04AB02severe
  • RifabutinJ04AB04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Bortezomib in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All bortezomib products

Authorised across Europe · EMA

The same active substance is authorised in 28 EEA countries. Names it is sold under:

  • Austria · Abormib, Bortezomib Ever Pharma
  • Belgium · Bortezomib Eg, Bortezomib Eugia
  • Bulgaria · Bortezomib Ever Pharma, Бортезомиб Актавис
  • Cyprus · Bortezomib Pharmazac, Bortezomib Stada
  • Czechia · Bortezomib Ever Pharma, Bortezomib Msn
  • Germany · Bortezomib, Bortezomib Amarox
  • Denmark · Bortezomib Actavis, Bortezomib Ever Pharma
  • Spain · Bortezomib Aurovitas, Bortezomib Combix
  • France · Bortezomib, Bortezomib Arrow
  • United Kingdom (Northern Ireland) · Bortezomib, Bortezomib Accord
  • Greece · Bortezomib Pharmazac, Bortezomib Sandoz
  • Croatia · Bortezomib Alpha-Medical, Bortezomib Ever Pharma
  • Hungary · Bortezomib Ever Pharma, Bortezomib Msn
  • Ireland · Bortezomib Aspire Pharma (Malta), Bortezomib Biotech Pharma Limited
  • Iceland · Bortezomib Accord, Bortezomib Actavis
  • Italy · Bortezomib Aurobindo, Bortezomib Dr. Reddy’s
  • Liechtenstein · Bortezomib Accord, Bortezomib Fresenius Kabi
  • Luxembourg · Bortezomib Eg
  • Latvia · Bortezomib Tzf
  • Malta · Bortezomib Clonmel, Bortezomib Dr. Reddy’s
  • Netherlands · Bortezomib Amarox, Bortezomib Cf
  • Norway · Bortezomib Accord, Bortezomib Ever Pharma
  • Poland · Adabonib, Bortezomib Eugia
  • Portugal · Bortezomib Ever Pharma, Bortezomib Extrovis
  • Romania · Bortezomib, Bortezomib Dr. Reddy’s
  • Sweden · Bortezomib Avansor, Bortezomib Ever Pharma
  • Slovenia · Bortezomib Actavis, Bortezomib Ever Pharma
  • Slovakia · Bortezomib Ever Pharma, Bortezomib Glenmark

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cd9f781f-563c-4b04-b74e-abed55bd2d3d
GET /v1/drugs/cd9f781f-563c-4b04-b74e-abed55bd2d3d?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "injektioneste, liuos",
  "route": "Ihon alle",
  "ddd_unit": null,
  "strength": "2.5 mg/ml",
  "atc_label": "bortetsomibi",
  "ma_number": "43054",
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": null,
  "fimea_rel_id": "REL62120",
  "authorised_at": "2025-01-02"
}

See everything about bortezomib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.